Carnitine deficiency provokes cisplatin-induced hepatotoxicity in rats

Basic and Clinical Pharmacology and Toxicology

Volumn 100, Issue 3, 2007, Pages 145-150

  Al Majed, Abdulhakeem A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE AMINOTRANSFERASE; CARNITINE; CISPLATIN; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; NITRATE; NITRITE; PROPIONYLCARNITINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARNITINE DEFICIENCY; CONTROLLED STUDY; DISEASE ASSOCIATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; RISK FACTOR; TISSUE STRUCTURE;

ADENOSINE TRIPHOSPHATE; ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CARNITINE; CISPLATIN; DISEASE MODELS, ANIMAL; GAMMA-GLUTAMYLTRANSFERASE; GLUTATHIONE; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; NITRATES; NITRITES; OXIDATIVE STRESS; RATS; RATS, WISTAR; RISK FACTORS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; VITAMIN B DEFICIENCY;

RATTUS;

EID: 33847061647     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.00024.x     Document Type: Article

References (35)

1. Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Ann Intern Med 1984;100:704-13.
2. Berliner S, Rahima M, Sidi Y et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest 1990;8:583-6.
3. Lee JE, Nakagawa T, Kim TS et al. Role of reactive radicals in degeneration of the auditory system of mice following cisplatin treatment. Acta Otolaryngol 2004;124:1131-5.
4. Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988;61:2192-5.
5. Schlaeffer F, Tovi F, Leiberman A. Cisplatin-induced bradycardia. Drug Intell Clin Pharm 1983;17:899-901.
6. Cersosimo RJ. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 1993;27:438-41.
7. Yilmaz HR, Sogut S, Ozyurt B et al. The activities of liver adenosine deaminase, xanthine oxidase, catalase, superoxide dismutase enzymes and the levels of malondialdehyde and nitric oxide after cisplatin toxicity in rats: protective effect of caffeic acid phenethyl ester. Toxicol Ind Health 2005;21:67-73.
8. Lu Y, Cederbaum AI. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol Sci 2006;89:515-23.
9. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004;195:221-30.
10. Heuberger W, Berardi S, Jacky E, Pey P, Krahenbuhl S. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 1998;54:503-8.
11. Goa KL, Brogden RN. L-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism. Drugs 1987;34:1-24.
12. Arafa HM, Sayed-Ahmed MM. Protective role of carnitine esters against alcohol-induced gastric lesions in rats. Pharmacol Res 2003;48:285-90.
13. Arockia Rani PJ, Panneerselvam C. Carnitine as a free radical scavenger in aging. Exp Gerontol 2001;36:1713-26.
14. Vanella A, Russo A, Acquaviva R et al. L-propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector. Cell Biol Toxicol 2000;16:99-104.
15. Yasui F, Matsugo S, Ishibashi M et al. Effects of chronic acetyl-L-carnitine treatment on brain lipid hydroperoxide level and passive avoidance learning in senescence-accelerated mice. Neurosci Lett 2002;334:177-80.
16. Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res 2006;53:278-86.
17. Sayed-Ahmed MM, Eissa MA, Kenawy SA, Mostafa N, Calvani M, Osman AM. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemotherapy 2004;50:162-70.
18. Paulson DJ, Shug AL. Tissue specific depletion of L-carnitine in rat heart and skeletal muscle by L-carnitine. Life Sci 1981;28:2931-8.
19. Tsoko M, Beauseigneur F, Gresti J et al. Enhancement of activities relative to fatty acid oxidation in the liver of rats depleted of L-carnitine by D-carnitine and γ-butyrobetaine hydroxylase inhibitor. Biochem Pharmacol 1995;49:1403-10.
20. Whitmer JT. L-carnitine treatment improves cardiac performance and restores high-energy phosphate pools in cardiomyopathic Syrian hamster. Circ Res 1987;61:396-408.
21. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957;28:56-63.
22. Szasz G. A kinetic photometric method for serum γ-glutamyl transpeptidase. Clin Chem 1969;15:124-36.
23. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
24. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70-7.
25. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001;5:62-71.
26. Alhomida AS. Study of the effects of theophylline-related changes in total, free, short-chain acyl and long-chain acyl carnitine concentrations in rat heart. Toxicology 1997;121:205-13.
27. Longo A, Bruno G, Curti S, Mancinelli A, Miotto G. Determination of L-carnitine, acetyl-L-carnitine and propionyl-L- carnitine in human plasma by high-performance liquid chromatography after pre-column derivatization with 1-aminoanthracene. J Chromatogr B Biomed Appl 1996;686:129-39.
28. Botker HE, Kimose HH, Helligso P, Nielsen TT. Analytical evaluation of high energy phosphate determination by high performance liquid chromatography in myocardial tissue. J Mol Cell Cardiol 1994;26:41-8.
29. Ahmida MH, Abdel-Gayoum AA, El-Fakhri MM. Effect of spironolactone on cisplatin-induced nephrotoxicity in rabbits. Hum Exp Toxicol 2001;20:453-9.
30. Zicca A, Cafaggi S, Mariggio MA et al. Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats. Eur J Pharmacol 2002;442:265-72.
31. Fenoglio C, Boncompagni E, Chiavarina B, Cafaggi S, Cilli M, Viale M. Morphological and histochemical evidence of the protective effect of procainamide hydrochloride on tissue damage induced by repeated administration of low doses of cisplatin. Anticancer Res 2005;25:4123-8.
32. Koc A, Duru M, Ciralik H, Akcan R, Sogut S. Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats. Mol Cell Biochem 2005;278:79-84.
33. Yildirim Z, Sogut S, Odaci E et al. Oral erdosteine administration attenuates cisplatin-induced renal tubular damage in rats. Pharmacol Res 2003;47:149-56.
34. Watanabe K, Hess A, Bloch W, Michel O. Expression of inducible nitric oxide synthase (iNOS/NOS II) in the vestibule of guinea pigs after the application of cisplatin. Anticancer Drugs 2000;11:29-32.
35. Tanphaichitr V, Broquist HP. Site of carnitine biosynthesis in the rat. J Nutr 1974;104:1669-73.